Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Breast Neoplasms 4Small Cell Lung Carcinoma 3Neoplasms 2Neoplasm Metastasis 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Oligodendroglioma 1Malignant Solid Tumor 1Glioblastoma 1Carcinoma 1Brain Neoplasms 1Astrocytoma 1Advanced Cancer 1

Interventions

pembrolizumab 156Gemcitabine 139Capecitabine 121Paclitaxel 119Fluorouracil 116Oxaliplatin 110Bevacizumab 104Nivolumab 97Leucovorin 97Docetaxel 93Cisplatin 90Irinotecan 88Carboplatin 85Radiosurgery 83Cyclophosphamide 71Cetuximab 70Magnetic Resonance Spectroscopy 68Trastuzumab 56Specimen Handling 56Biopsy 56Radiotherapy 55Ipilimumab 52Everolimus 48Pemetrexed 46Drug Therapy 45Albumin-Bound Paclitaxel 44130-nm albumin-bound paclitaxel 43Doxorubicin 41Fulvestrant 38aldesleukin 37

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × Neoplasm Metastasis × etirinotecan pegol × Clear all
NCT02915744 2023-04-14

ATTAIN

Nektar Therapeutics

Phase 3 Completed
178 enrolled 37 charts
Breast

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT01773109 2020-04-03

Etirinotecan Pegol (NKTR-102) in NSCLC

Abramson Cancer Center at Penn Medicine

Phase 2 Completed
40 enrolled 9 charts
Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡